Objectives Up to 77% of patients with obstructive sleep apnoea (OSA) have positional OSA (POSA) but traditional positional therapy (PT) methods have failed as they were poorly tolerated. New convenient vibratory PT devices have been invented but while recent studies suggest high treatment efficacy and adherence, there are no published data comparing these devices directly with continuous positive airway pressure (CPAP). Our objective is to evaluate if a convenient vibratory PT device is non-inferior to CPAP in POSA treatment. Methods In this crossover randomised controlled trial, we enrolled patients with POSA with significant daytime sleepiness (Epworth Sleepiness Scale (ESS)≥10). POSA diagnosis was based on: (1) total Apnoea/Hypopnoea Index (AHI)>10/hour and non-supine AHI<10/hour (2) supine AHI≥2 × non-supine AHI. Patients used their initial allocated devices (PT or CPAP) for 8 weeks before crossing to the alternative intervention after a 1 week washout. The primary aim is to measure changes in ESS between the two treatments. Secondary outcomes include sleep study parameters and patient treatment preference (ClinicalTrials.gov: NCT03125512). Results 40 patients completed the trial between April 2017 and December 2018. Difference in ESS after 8 weeks of device use (PT minus CPAP) was 2.0 (95% CI 0.68 to 3.32), exceeding our predetermined non-inferiority margin of 1.5. AHI on CPAP was lower than with PT (4.0±3.2 vs 13.0±13.8 events/hour, respectively, p=0.001), although both were lower than at baseline. Time spent supine was significantly lower with PT than CPAP (p<0.001). 60% of patients preferred CPAP, 20% preferred PT, while 20% preferred neither device. Conclusions The non-inferiority ESS endpoint for PT compared with CPAP was not met and the results were inconclusive. Future trials with larger sample sizes or in less symptomatic patients are warranted to provide further insight into the role of these new vibratory PT devices.
Purpose Home sleep apnoea test (HSAT) is an effective diagnostic test for obstructive sleep apnoea (OSA). However, a proportion of patients who undergo HSAT may obtain an inconclusive result and require further diagnostic testing. Our objective is to evaluate the proportion of patients who have an inconclusive HSAT and complete diagnostic testing with an in-laboratory polysomnogram. Methods Patients who had HSAT performed for suspected OSA and obtained an inconclusive test (technically inadequate study or low pAHI less than 5) were included. Rates of completion of diagnostic testing, factors associated with completion of diagnostic testing and rates of OSA in patients who completed diagnostic testing were evaluated. Results 139 patients (106 male and 33 female, age 38 ± 27, body mass index 25.6 ± 7.9 kg/m2) with inconclusive HSAT were included. Only 35 patients (25.2%) completed diagnostic testing after the inconclusive HSAT. Multivariate analysis showed male gender, individuals at elevated risk of moderate to severe OSA and those who were previously counseled about the need for repeat testing had significantly higher odds of completing diagnostic testing. 20 out of 35 patients (57%) who completed diagnostic testing had moderate to severe OSA. Conclusion A considerable percentage of patients with an inconclusive HSAT failed to complete diagnostic testing, which puts them at risk of missing out on a diagnosis of OSA and potential treatment. Physicians should be aware of this limitation when choosing a diagnostic test for suspected OSA.
Background/Objectives: Home non-invasive ventilation use is the primary treatment for improving respiratory function in people with chronic hypercapnic respiratory failure. Non-invasive ventilation has also been studied to understand users’ perspectives. However, no studies have been conducted on how users adapt to non-invasive ventilation in their homes from the early phase of their diagnosis as a long-term utility. Methods: The study employed a descriptive qualitative design guided by Roy’s adaptation model. A purposive sample was used. People with chronic hypercapnic respiratory failure who had used NIV at home for a minimum of six months would be eligible. They were interviewed at a sleep and assisted ventilation centre. Their interviews were audio recorded before proceeding with transcription. Each transcript was thematically analysed. Results: Twenty participants were included in the study, from which six themes emerged. They experienced a common transition, from denying the need for non-invasive ventilation to integrating them into their daily lives at home. Throughout this process, they had emotional turmoil, faced difficulties in keeping their masks on, and improved sleep quality. They also adjusted their social interactions before fully accepting the use of non-invasive ventilation. Their coping strategies in their role functions at home and social interaction were also narrated. Their family members were pivotal in their adaptation period. Conclusions: Gaining insight into individuals’ adaptation experiences can facilitate early identification of potential challenges faced by new users of non-invasive ventilation. This study calls for healthcare professionals to assess users’ understanding of long-term commitment and their living conditions early for a successful NIV adaptation.
Background: Patients with exertional hypoxaemia (EH) at hospital discharge face rapid deconditioning risks. However, early pulmonary rehabilitation (PR) is limited by exercise intolerance and access barriers. Optimal PR design for this group remains unclear. High‐flow nasal oxygen (HFO) may alleviate EH, but its role in home‐based PR is unexplored. We aimed to evaluate an early, intensive, home‐based PR program and the integration of HFO during exercise training for EH patients post‐hospitalisation. Methods: In this pilot feasibility trial, EH patients across respiratory conditions were randomised to PR with HFO (HFO‐PR) or PR alone (PR‐only). Both groups commenced a three‐week home‐based PR program (two supervised, three self‐directed sessions weekly) within 1 week of discharge. Feasibility was assessed using quantitative and qualitative measures. Results: Fifty‐two of 56 patients completed follow‐up at 4 weeks. Overall PR program acceptance and uptake were 67% and 62%, respectively. Program completion was lower in the HFO‐PR group (60%) compared to the PR‐only group (89%), primarily due to reduced adherence to self‐directed exercise sessions. Among COPD patients, the 1‐min sit‐to‐stand test at 4 weeks improved by 4.6 repetitions in the HFO group and 5.3 in the PR‐only group (adjusted difference in mean change −0.8, 95% CI −4.7 to 3.1). Qualitative findings revealed three themes: Transformations following the intervention, Receiving care and education at home, and Experiencing HFO system. Participants reported challenges with HFO during unsupervised exercise. Conclusion: Early home‐based PR for post‐hospitalisation EH patients is feasible and safe. However, the addition of HFO was associated with lower adherence, highlighting implementation barriers to address before further evaluation. Trial Registration: NCT05752370
28 September 2023 in Proceedings of Singapore Healthcare
Introduction: Early pulmonary rehabilitation (PR) is guideline-recommended for all chronic obstructive pulmonary disease (COPD) patients post-hospitalization for COPD exacerbation but many patients experience difficulties participating in early PR due to significant breathlessness. High flow nasal oxygen (HFO) has been shown to improve ventilatory efficiency in stable COPD patients, but there is little data on HFO use during exercise training in PR post-COPD exacerbation. Methods: We conducted a pilot randomized controlled trial (RCT) to explore the feasibility of a prospective large-scale RCT to evaluate the impact of HFO in improving PR outcomes of COPD patients post-exacerbation. Patients recently hospitalized for COPD exacerbation were enrolled and randomized to either HFO or usual care during an early 6-weeks, outpatient PR program. Results: Twenty two patients were randomized between May 2019 to Dec 2019 and 18 patients completed the study. The HFO arm achieved a greater improvement in exercise capacity than the usual care arm, with the mean difference in 6-min walk distance (6MWD) being 30 m (95% CI: −23 m to 84 m), although this was not statistically significant. All 18 patients in both arms were compliant to the pulmonary rehabilitation program (defined by attending ≥75% of exercise sessions). HFO was well tolerated with no adverse events reported. Conclusion: This pilot RCT has shown preliminary evidence of the feasibility and high patient acceptability of HFO during early PR on improving exercise capacity in COPD patients post-exacerbation These promising results would justify a larger RCT to confirm HFO’s benefits and has the potential to change PR practice.